top of page

TPEXTREME RANDOMIZED TRIAL PUBLISHED IN LANCET

April 2021


Taxane-based TPEx regimen appears to be a new option in first line recurrent/metastatic HNSCC, with a shorter time on therapy and lower toxicity than the reference EXTREME regimen. This can provide an alternative to SOC with EXTREME regimen, especially for those who may not be good candidates for up-front pembrolizumab. https://pubmed.ncbi.nlm.nih.gov/33684370/

5 views

Recent Posts

See All
bottom of page